Results 161 to 170 of about 38,538 (308)
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino +13 more
wiley +1 more source
Bispecific single-domain antibody (VHH) fused with human IgG1 Fc with dual specificity effectively neutralize Naja Kaouthia venom. [PDF]
Pothisamutyothin K +4 more
europepmc +1 more source
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta +14 more
wiley +1 more source
A potent Gc neutralizing antibody reveals architecture-dependent bispecific protection against SFTSV. [PDF]
Lu H +20 more
europepmc +1 more source
Proteolytic remodelling of the extracellular matrix by pericytes
Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard +4 more
wiley +1 more source
Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges. [PDF]
Rotte A, Sopjani M, Bhandaru M.
europepmc +1 more source
Bispecific antibody toxicities
Britto, Joanne +3 more
openaire +2 more sources
FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita +2 more
wiley +1 more source
Erratum for Li et al., "Bispecific antibodies targeting MPXV A29 and B6 demonstrate efficacy against MPXV infection". [PDF]
Li M +8 more
europepmc +1 more source
ABSTRACT Introduction Recent advances in prophylaxis with clotting factor concentrates have enabled people with haemophilia (PwH) to participate in high‐intensity exercises; however, this does not preclude them from sports‐induced bleeding (SIB). Aim To investigate factors influencing the recent occurrence of SIB among PwH.
Rie Shirayama +3 more
wiley +1 more source

